Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr70.00 SEK
Change Today 0.00 / 0.00%
Volume 133.3K
ORX On Other Exchanges
As of 11:29 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

orexo ab (ORX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/29/15 - kr149.25
52 Week Low
09/15/15 - kr42.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OREXO AB (ORX)

Related News

No related news articles were found.

orexo ab (ORX) Related Businessweek News

No Related Businessweek News Found

orexo ab (ORX) Details

Orexo AB (publ)., a specialty pharmaceutical company, engages in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. The company’s product portfolio comprises products on the market, proprietary development programs, and collaboration projects. Its products on the market include Zubsolv sublingual tablets for maintenance treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem and for the treatment of short-term insomnia. The company’s development programs comprise OX51, a sublingual formulation containing alfentanil, which has completed phase II study for the prevention of acute intense pain associated with care-related diagnostic or therapeutic procedures. Its collaboration projects consist of OX-MPI for the treatment of pain and inflammation through collaboration with Boehringer Ingelheim; OX-NLA for the treatment of allergic and non-allergic rhinitis through a partnership with Meda AB; and OX-CLI for the respiratory tract diseases through collaboration with AstraZeneca. Orexo AB (publ). was founded in 1995 and is headquartered in Uppsala, Sweden.

94 Employees
Last Reported Date: 10/22/15
Founded in 1995

orexo ab (ORX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.1M
Compensation as of Fiscal Year 2014.

orexo ab (ORX) Key Developments

Orexo AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 2015

Orexo AB announced earnings results for the third quarter and nine months ended September 2015. Net revenues of SEK 139.5 million compared to SEK 130.7 million a year ago. LBIT was SEK 39.4 million compared to SEK 29.3 million a year ago. LBITDA was SEK 33.9 million compared to SEK 26.8 million a year ago. Loss after tax was SEK 46.1 million or SEK 1.33 per share compared to SEK 36.8 million or SEK 1.13 per share a year ago. Cash outflow from operating activities was SEK 79.5 million compared to SEK 152.1 million a year ago. For the nine months, the company reported net revenues of SEK 415 million compared to SEK 349.8 million a year ago. LBIT was SEK 124.7 million compared to SEK 84 million a year ago. LBITDA was SEK 113.1 million compared to SEK 76.6 million a year ago. Loss after tax was SEK 146.2 million or SEK 4.24 per share compared to SEK 108.2 million or SEK 3.37 per share a year ago. Cash outflow from operating activities was SEK 108.5 million compared to SEK 480 million a year ago.

Orexo Names Members of Nomination Committee

Orexo AB announced that the members of its nomination committee, prior to the Annual General Meeting 2016, are Eivind Kolding of Novo A/S and also chairman of the nomination committee; Björn Odlander of HealthCap; Claus Berner Maller of Arbejdsmarkedets Tillaegspension (ATP) and Martin Nicklasson, chairman of the board of directors of Orexo.

Orexo AB Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-18-2015

Orexo AB Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-18-2015 . Venue: The May Fair Hotel, Stratton Street, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORX:SS kr70.00 SEK 0.00

ORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OREXO AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at